Platelet Aggregation Devices Market, By Product (Systems, Reagents, and Consumables and Accessories), By Application (Clinical Applications and Research Applications), By End User (Hospitals, Diagnostic Laboratories, and Other End Users), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
A platelet aggregation test is a blood test that looks at how well blood cells called platelets clump together and clot. Platelet tests check for conditions that cause too much bleeding or too much blood clotting. The test checks how well platelets, a part of blood, clump together, and cause blood to clot. Thus, platelet aggregation devices are often used to treat bleeding disorders. A variety of tests are available but there is no one test that identifies all problems with platelet function.
Market Dynamics:
Growing burden of bleeding disorders, increasing incidence of chronic diseases, growing geriatric population, and rise in demand for platelet aggregation devices across the globe are major factors expected to drive growth of the global platelet aggregation devices market.
For instance, in February 2022, Futura Surgicare launched hemostatic products under the brand Hemostax (Oxidized Regenerated Cellulose) under a new vertical, Dolphin Hemostats. Hemostax Standard is an absorbable hemostat designed to help surgeons control bleeding more efficiently.
In July 2021, Baxter International reported its Baxter Healthcare Corporation subsidiary acquired certain assets related to the PerClot Polysaccharide Hemostatic System from CryoLife, Inc. The PerClot Polysaccharide Hemostatic System is used to control bleeding during surgical procedures, including gynecologic, general, cardiovascular, and urology.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook